Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2017. cited 2018 Jun 4th. Available from: http://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf
   Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450–504.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH. Striverdi respimat (olodaterol) inhalation spray for oral inhalation: US prescribing information. 2014. [cited 2018 May 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203108s000lbl.pdf
   Google Scholar
• Boehringer Ingelheim International GmbH. Striverdi respimat 2.5 microgram, solution for inhalation: EU summary of product characteristics. 2013. [cited 2018 May 31th]. Available from: http://mri.medagencies.org/Human
   Google Scholar
• Deeks ED. Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs. 2015;75:665–673.
   PubMed Web of Science ®Google Scholar
• Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334(1):53–62.
   PubMed Web of Science ®Google Scholar
• Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337(3):600–97b.
   PubMed Web of Science ®Google Scholar
• Wex E, Kollak I, Duechs MJ, et al. The long-acting β2-adrenoceptor agonist olodaterol attenuates pulmonary inflammation. Br J Pharmacol. 2015;172(14):3537–47.
   PubMed Web of Science ®Google Scholar
• Matera MG, Ora J, Cazzola M. Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol. Ther Clin Risk Manag. 2015;11:1805–11.
   PubMed Web of Science ®Google Scholar
• Borghardt JM, Weber B, Staab A, et al. Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. Br J Clin Pharmacol. 2016;81(3):538–52.
   PubMed Web of Science ®Google Scholar
• van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24(6): 666–72.
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR, Beck E, Hamilton AL, et al. A randomised, placebo-controlled, phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109:596–605.
   PubMed Web of Science ®Google Scholar
• Borghardt JM, Weber B, Staab A, et al. Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation. Br J Clin Pharmacol. 2016;82(3):739–53.
   PubMed Web of Science ®Google Scholar
• Borghardt JM, Weber B, Staab A, et al. Pharmacometric models for characterizing the pharmacokinetics of orally inhaled drugs. AAPS J. 2015;17(4):853–70.
   PubMed Web of Science ®Google Scholar
• Kunz C, Luedtke D, Unseld A, et al. Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function. Int J Chron Obstruct Pulmon Dis. 2016;11:585–95.
   PubMed Web of Science ®Google Scholar
• Ng TM, Munger MA, Lombardi WL, et al. Chronically inhaled salmeterol improves pulmonary function in heart failure. J Cardiovasc Pharmacol. 2002;40:140–145.
   PubMed Web of Science ®Google Scholar
• Maltais F, Buhl R, Koch A, et al. β-blockers in COPD: A cohort study from the TONADO research program. Chest. 2018 Jan 31 pii: S0012-3692(18)30080-1. DOI:10.1016/j.chest.2018.01.008
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Beta-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution. Am J Respir Crit Care Med. 2008;178:661–662.
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255.
   PubMed Web of Science ®Google Scholar
• Joos GF, Aumann JL, Coeck C, et al. A randomised, double-blind, four-way, crossover trial comparing the 24-hours FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109(5):606–615.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9: 629–45.
   PubMed Web of Science ®Google Scholar
• Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697–714.
   PubMed Web of Science ®Google Scholar
• Feldman GJ, Bernstein JA, Hamilton A, et al. The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies. Springerplus. 2014;3:419.
   PubMedGoogle Scholar
• Lange P, Aumann J-L, Hamilton A, et al. The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J Pulm Resp Med. 2014;4:4.
   Google Scholar
• Maltais F, Kirsten A-M, Hamilton AL, et al. Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week studies. Respir Res. 2016;17:77.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53–59.
   PubMed Web of Science ®Google Scholar
• Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Randomized, double-blind, dose-finding study for tiotropium when added to olodaterol, administered via the Respimat® inhaler in patients with chronic obstructive pulmonary disease. Adv Ther. 2015;32(9):809–22.
   PubMed Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–979.
   PubMed Web of Science ®Google Scholar
• O’Donnell D, Casaburi R, De Sousa D, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017 Apr;49(4). Epub 2017 Apr 19 pii: 1601348. DOI:10.1183/13993003
   Web of Science ®Google Scholar
• Punekar YS, Sharma S, Pahwa A, et al. Rescue medication use as a patient-reported ooutcome in COPD: a systematic review and regression analysis. Respir Res. 2017;18:86.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. TORCH. N Engl J Med. 2007;356(8):775–89.
   PubMed Web of Science ®Google Scholar
• Decramer ML, Chapman KR, Dahl R, et al. for the INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524–33.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhong N-S, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 2017;377:923–935.
   PubMed Web of Science ®Google Scholar
• Hw L, Hj K, Ch L. The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis. Br J Clin Pharmacol. 2017;83(6):1166–117.
   PubMed Web of Science ®Google Scholar
• McGarvey L, Niewoehner D, Magder S, et al. One-year safety of olodaterol once daily via Respimat® in patients with GOLD 2–4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysis. COPD. 2015;12(5):484–493.
   PubMedGoogle Scholar
• Andreas S, Bothner U, Trampisch M, et al. Effect of long-acting β2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. Pulm Pharmacol Ther. 2018 Aug 2. pii: S1094-5539(18)30058-0. doi: 10.1016/j.pupt.2018.08.002.
   PubMedGoogle Scholar
• Tashkin DP, Celli B, Senn S, et al. for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Buhl R, Magder S, Bothner U, et al. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2017;122:58–66.
   PubMed Web of Science ®Google Scholar
• Koch A, Watz H, Maleki-Yazdi MR, et al. Comprehensive assessment of the safety of olodaterol 5 μg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol. Npj Prim Care Respir Med. 2017;27:60.
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. on behalf of the gruppo educazionale Associazione Italiana Pneumologi Ospedalieri (AIPO). Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938.
   PubMed Web of Science ®Google Scholar
• Wachtel H, Kattenbeck S, Dunne S, et al. The Respimat® development story: patient-centered innovation. Pulm Ther. 2017;3:19–30.
   Google Scholar
• Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real life assessment of 2935 patients. Eur Respir J. 2017;49(2). pii: 1601794. DOI:10.1183/13993003.01794-2016
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Small M, Milligan G, et al. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108:358–365.
   PubMed Web of Science ®Google Scholar
• Anderson P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev. 2005;14(96):109–116.
   Google Scholar
• Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:381–390.25.
   PubMedGoogle Scholar
• Dal Negro RW, Povero M. Acceptability and preference of three inhalation devices assessed by the handling questionnaire in asthma and COPD patients. Multidiscip Respir Med. 2016;11:7.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Maltais F, Porszasz J, et al. The continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trial. PLoS One. 2014;9(5):e96574.
   PubMed Web of Science ®Google Scholar
• Troosters T, Sciurba F, Battaglia S, et al. Physical inactivity in patients with COPD: a controlled multi-center pilot study. Respir Med. 2010;104:1005–1011.
   PubMed Web of Science ®Google Scholar
• Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140(7):331–342.
   PubMedGoogle Scholar
• Decramer M, Celli B, Kesten S, et al. for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–8.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Kunisaki KM, Strand MJ, et al. for the COPDGene Investigators. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(3):324–330.
   PubMed Web of Science ®Google Scholar
• Kruis AL, Ställberg B, Jones RC, et al. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One. 2014;9(3):e9014e.
   Web of Science ®Google Scholar
• Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in central and Eastern Europe: the POPE study. Eur Respir J. 2017 May 11;49(5). pii: 1601446.
   Web of Science ®Google Scholar
• Roskell NS, Anzueto A, Hamilton A, et al. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J Chron Obstruct Pulmon Dis. 2014;9:813–824.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Betts KA, Du EX, et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:367–381.
   PubMed Web of Science ®Google Scholar
• Feldman G, Siler T, Prasad N, et al. for the INLIGHT 1 study group. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10:11.
   PubMed Web of Science ®Google Scholar
• Wex E, Bouyssou T. Olodaterol attenuates citric acid-induced cough in naïve and ovalbumin-sensitized and challenged guinea pigs. PLoS One. 2015;10(3):e0119953.
   PubMed Web of Science ®Google Scholar